Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis Delta and 96 weeks of po…

H Wedemeyer, S Aleman, A Blank, P Andreone, P Bogomolov, V Chulanov, N Mamonova, N Geyvandova, V Morozov, O Sagalova, T Stepanova, A Berger, S Ciesek, K Deterding, A Lichtman, D Manuilov, R-C Mercier, S Arterburn, F Christian-Cox, S Tseng, A Osinusi, J Sculze… · Zeitschrift für Gastroenterologie · 2025 · Heft 08 · S. e557-e558